Cell cycle regulatory machinery

The cell cycle regulatory machinery is a sophisticated network of proteins and enzymes that governs the orderly progression of a cell through the phases of growth and division, including G1, S, G2, and M (Malumbres, 2014, Genome Biology). Central to this system are cyclin-dependent kinases (CDKs) and their regulatory subunits, cyclins, which form active complexes to phosphorylate substrates necessary for phase transitions (Morgan, 2007, The Cell Cycle: Principles of Control). This machinery also includes endogenous CDK inhibitors (CKIs), such as the p16 and p21 families, and various checkpoints that ensure DNA integrity and proper chromosome segregation before proceeding (Sherr & Roberts, 1999, Genes & Development). Dysregulation of these components, often through the overexpression of cyclins or the loss of tumor suppressors like Retinoblastoma (Rb) and p53, is a fundamental hallmark of cancer, leading to uncontrolled cellular proliferation (Hanahan & Weinberg, 2011, Cell). Consequently, this machinery is a major focus of oncology therapeutics, with drugs like CDK4/6 inhibitors (e.g., palbociclib, ribociclib) designed to induce cell cycle arrest in malignant cells (O'Leary et al., 2016, Nature Reviews Clinical Oncology). While these therapies have transformed the treatment of certain cancers, they are associated with challenges such as dose-limiting myelosuppression and the eventual development of acquired resistance (Asghar et al., 2015, Nature Reviews Drug Discovery).

Other names

Cell cycle control systemCell cycle regulatorsCell cycle machineryCDK-Cyclin complexes

Drugs targeting this machinery act through various mechanisms, most notably the competitive inhibition of the ATP-binding site of cyclin-dependent kinases (CDKs), which prevents the phosphorylation of the Retinoblastoma (Rb) protein and halts the G1-to-S phase transition. Other agents may stabilize or destabilize microtubules to disrupt mitosis or inhibit DNA synthesis enzymes to trigger S-phase arrest (O'Leary et al., 2016, Nature Reviews Clinical Oncology; Asghar et al., 2015, Nature Reviews Drug Discovery).